What’s going on at biotech’s lobbying organization? Where does mRNA go from here? And what happens when startups close down?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. STAT Washington correspondent Rachel Cohrs joins us to explain the abrupt departure of the CEO of BIO, the lobbying group representing biotech on Capitol Hill, and its wider implications. We also discuss the latest news in the life sciences, including the future of mRNA, a promising startup closing its doors, and Biogen’s search for a new CEO.
mRNA is paving the way for an explosion in manufacturing capacity and demand
With recent advances in mRNA set to spark a surge in new medicines, the biopharma industry is expanding capacity to meet future demand. Scott Ripley, general manager of nucleic acid therapeutics at Cytiva, says companies are getting ready by investing in more agile manufacturing solutions that can support diverse production needs, from making a personalized dose for a single patient to large batches of a mass-market vaccine. Learn more about how biopharma and governments are preparing for a future of fast growth.
No comments